Barclays PLC Mereo Biopharma Group PLC Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Barclays PLC holds 38 shares of MREO stock, worth $109. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 38 -0.0%

Holding current value

$109

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$1.19 - $2.42 $45 - $91	-38 Reduced 50.0%	38 $0
Q3 2023 Nov 07, 2023	BUY	$1.15 - $1.67 $43 - $63	38 Added 100.0%	76 $0
Q2 2023 Aug 03, 2023	SELL	$0.79 - $1.43 $150,075 - $271,655	-189,969 Reduced 99.98%	38 $0
Q1 2023 May 04, 2023	BUY	$0.71 - $1.22 $16,589 - $28,506	23,366 Added 14.02%	190,007 $134,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $1.01 $63,585 - $128,442	127,171 Added 322.2%	166,641 $125,000
Q3 2022 Nov 03, 2022	BUY	$0.82 - $1.73 $15,965 - $33,683	19,470 Added 97.35%	39,470 $34,000
Q2 2022 Aug 12, 2022	SELL	$0.33 - $1.69 $134,008 - $686,283	-406,085 Reduced 95.31%	20,000 $22,000
Q1 2022 May 16, 2022	BUY	$1.04 - $1.7 $55,422 - $90,594	53,291 Added 14.3%	426,085 $477,000
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.59 $532,718 - $913,736	352,794 Added 1763.97%	372,794 $596,000
Q2 2021 Aug 13, 2021	SELL	$2.94 - $4.08 $173,424 - $240,671	-58,988 Reduced 74.68%	20,000 $63,000
Q1 2021 May 13, 2021	BUY	$2.6 - $4.43 $205,368 - $349,916	78,988 New	78,988 $266,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $4.14 $17 - $33	-8 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.52 - $6.5 $20 - $52	8 New	8 $0

Others Institutions Holding MREO

# of Institutions

Shares Held

107M

Call Options Held

209K

Put Options Held

479K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $360M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account